RxDoctor Payments Data

Julie Mermilliod, MD

Dermatology · New Orleans, LANPI 1578514808

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $153,125 of the $221,874 with a category attached, or 69.0%. Lilly USA, LLC accounts for 93.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $83,276 and has fallen 78.8% since, to $17,688 in 2025. Among dermatology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$221,875in general payments, 2019–2025

Across 449 payments — averaging $494.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$206K
  • Novartis$8K
  • Eli Lilly$3K
  • Johnson & Johnson$2K
  • AbbVie$509
  • E.r. Squibb & Sons, L.L.C.$387
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$25,42511%
  • Speaking & faculty fees$153,12569%
  • Travel & lodging$35,49516%
  • Food & beverage$7,6193%
  • Education$2100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$221,875 in reported general payments places this provider in the 95th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$65,423
Medicare patients
365
Services billed
1,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab29$328,095
Cosentyx Unoready PenSecukinumab33$302,017
Skyrizi PenRisankizumab-Rzaa11$222,239
Cosentyx Sensoready (2 Pens)Secukinumab22$167,968
Taltz AutoinjectorIxekizumab24$162,717
StelaraUstekinumab11$147,810
Dupixent PenDupilumab20$73,356
OtezlaApremilast15$65,857
Clobetasol Propionate106$3,669
Triamcinolone Acetonide215$2,678
Acitretin15$2,080
Clindamycin Phosphate44$1,644
Ketoconazole101$1,629
Imiquimod47$1,349
MethotrexateMethotrexate Sodium98$913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$2,318$147,81011 claims
AmgenOtezla$365$65,85715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 189 dermatology providers in Louisiana.

Other dermatology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →